Litcius/Paper detail

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

J.F.R. Robertson, Robert Paridaens, Jasmine Lichfield, Ian Bradbury, Christine Campbell

2021European Journal of Cancer16 citationsDOIOpen Access PDF

Topics & Concepts

TamoxifenMedicineAromataseOncologyBreast cancerEndocrine systemInternal medicinePostmenopausal womenAromatase inhibitorCancerMeta-analysisHormone receptorGynecologyHormoneEstrogen and related hormone effectsBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer | Litcius